Introduction Primary Sclerosing Cholangitis (PSC) is a rare and chronic disease characterised by inflammation and fibrosis of the liver's bile ducts. There is no known cause or cure for the illness, which often progresses to end-stage liver disease requiring liver transplantation.
Strengths and limitations:
 This study will employ innovative qualitative research methods, such as the use of asynchronous virtual focus groups (AVFGs), to capture the lived experiences of those with a rare illness spread over a large geographic space who would not be able to participate in a study like this otherwise.  A triangulated perspective will be used to explore the experiences of those living with PSC, caregivers and health professionals, with a view to improving the support provided to all.  A personalised psychological intervention, that can be tailored to fit individuals' personal circumstances, will be created in response to analysing these experiences.  However, involvement in AVFGs is dependent on participants' literacy, computerliteracy and access to technology.  Although online qualitative approaches can target difficult-to-access populations, they cannot replace face-to-face human contact and interaction. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 F o r p e e r r e v i e w o n l y INTRODUCTION Primary Sclerosing Cholangitis (PSC) is a rare and chronic disease characterised by the narrowing and blockage of the liver's bile ducts from inflammation and fibrosis. 1 Recent estimates suggest that the incidence of PSC is 0.68 per 100,000 person-years. 2 It disproportionately affects men, and symptoms include jaundice, fatigue, and itching, among others. 1, 3 However, these symptoms vary: some people are asymptomatic when first diagnosed, whereas others have a significant symptom burden. 4 In addition to this variation in symptoms, the speed and aggressiveness with which the disease can progress may differ between individuals, with little indication from the literature as to why. 1 Furthermore, there is no curative treatment for PSC, with liver transplant offered as an option for those reaching endstage liver disease, with those living with the illness displaying a greater incidence of colorectal and biliary tract cancers in addition to other complications. 5, 6 In the absence of curative treatment, recent research has begun to examine the impact of living with PSC on individuals' psychological wellbeing. 7 Similar to other long-term physical illnesses, individuals living with PSC tend to report a greater number of depressive symptoms, and a greater level of impairments pertaining to quality of life and wellbeing compared to the general population. [7] [8] [9] Voices from lived experience reveal that the uncertainty with which the disease may progress to an eventual need for a liver transplant, and whether and when that transplant may be possible, can lead to considerable distress and anxiety regarding the future. 10, 11 In addition to such distress, individuals with PSC also report feeling socially isolated due to the rarity of the illness. 8, 12 Consequentially, such difficulties emphasise a need for access to emotional support that addresses this population's unmet needs and reinstalls hope in the future. 10 A need for greater access to support is likely also felt by those supporting individuals living with PSC, whether informally or formally. 7 Partners and families supporting those living with PSC may need to adjust and prepare for caring for a serious illness. Due to the rarity of the illness, few healthcare professionals will have experience of how PSC can present and progress, and so treating the presenting individual may result in unexpected challenges for them, especially in finding appropriate and effective pathways of care for their patient. 11 In light of these difficulties, the proposed study will aim to understand and chronicle the impact of PSC on the psychological wellbeing of those diagnosed with it and their caregivers, and on 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
METHODS and ANALYSIS

Procedure
This project will take a layered qualitative approach to understanding the ways in which people experience living with PSC within their day-to-day lives. There will be two stages to this study, which will also pilot a unique methodological process using online resources. The study duration is expected to be 18 months. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y   6 Stage One answers Research Questions 1, 2, and 3 and will comprise of:
Asynchronous virtual focus groups (AVFGs)(Research Questions 1 and 2)
AVFGs are focus groups held online over a time period that is longer than a usual focus group, usually one question per week over a period of several weeks. Similar to a traditional focus group, they still have set time limits and the ability for participants to engage with each other. They have been previously used successfully with vulnerable and diverse populations. 13 As PSC is so rare, conducting face-to-face research is difficult, so AVFGs are a good way of accessing as wide a group as possible. 14 
Separate
AVFGs will be conducted with both people living with PSC and family members to allow participants to be as open and honest in their responses as they wish.
AVFGs will be limited to 6-9 participants per group. Due to their online nature, more than one AVFG will be held at the same time. Four questions will be asked over four weeks to guide the discussion. Within the AVFG, one question will be posed per week and the participants can post as many responses as they wish each week; both in response to the question posed and what other responders have said. After a week, the previous question will be closed and the next one will be opened; this will be clearly stated. In this way, participants can respond when it suits them, with the responses being as long or as short as they feel comfortable with. The AVFGs will be moderated twice daily by researchers KM and VR to ensure participants' wellbeing, and every participant will have access to clear contact details for the research team and helplines (ie. Samaritans) should a participant become upset. All questions will focus on understanding the mental health and wellbeing (including feelings of hopelessness, anxiety, powerlessness, and resilience) of people with the disease and their partners and family members, and how these feelings have changed since diagnosis and potential changes in severity of symptoms.
2. Narrative interviews (telephone/online/face-to-face -more in-depth experience)
(answers Research Questions 1-3)
Narrative interviews are crucial to unpacking the themes identified from the AVFGs to inform the development of a personalised psychological intervention. Narrative interviews will be conducted with: with PSC who took part in AVFGs if they are willing to provide the name and contact details of their healthcare practitioner. As PSC is uncommon, it is expected that not every healthcare practitioner will be experienced in treating it, which can lead to feelings of stress when trying to determine the best pathway of care for their patient.
Healthcare professionals will not have access to any data disclosed during interviews and focus groups with participants who have PSC, and vice versa.
Stage Two answers Research Question 4, and is based on the findings from Stage One.
Practitioners from hepatology, gastroenterology and mental health will be invited to a presentation of the themes and narratives uncovered from the data in Stage One. Following this presentation, they will be asked to partake in an audio-recorded roundtable discussion on the findings of the focus groups and interviews. From these findings, they will be asked to help coconstruct a Personalised Psychological Intervention. After the completion of this roundtable, the researchers will write up the conclusions of the discussion and will send these to the practitioners for confirmation.
Sample
Participants will consist of those with lived experience of PSC, family members/partners/carers of people living with PSC, and health professionals who have experience working with people living with PSC. This study aims to empower those living with PSC and their loved ones and those who care for them to make their voices heard. As such, we are keeping our inclusion criteria general so as to include as many people who would like to participate as possible.
Participants must:
 Be aged 18 years or more  Be UK residents  Self-identify as someone living with PSC or a partner, family member or carer of a person living with PSC or a health professional working with people living with PSC Due to the rarity of this disease and the lack of extant research exploring experiences of PSC, it is difficult to specify the size of our sample. The study will aim to include a range of 37-62 participants overall. This range acknowledges that recruitment of individuals with PSC may be challenging given the rarity of the illness, but also ensures enough participation for data saturation. For the AVFGs we aim to run 2 -4 focus groups consisting of 6 -9 participants in each. This will include: 1 -2 focus groups of people living with PSC and 1 -2 focus groups of partners and family members of people living with PSC. From these, we plan on purposively sampling up to ten individuals to take part in narrative interviews. Additionally, we aim to interview 5 -10 health professionals.
Setting
Participants will be recruited using the PSC Support network. PSC Support is a charity that plays a key role in connecting people living with PSC to each other and wider PSC communities, as well as providing access to support and information. PSC Support will promote the study, as well as guide us on the appropriateness and relevance of the study design.
The study will be advertised via PSC Support's media presence (ie. Facebook and Twitter). All interested people can contact the researchers (KM and VR) directly to get more information about the study. All study specific activities (e.g. recruitment etc.) will be undertaken by the researchers who are based in the Tavistock and Portman NHS Foundation Trust. As PSC is a rare disease, participants will be recruited from across the United Kingdom to allow greater participation.
Asynchronous Virtual Focus Groups (AVFGs) will be hosted on an existing Virtual Learning Environment (VLE) (ie. Moodle or Blackboard). 15, 16 VLEs are suitable for collecting this type of data as they enable researchers to host focus groups on their own custom-made site which is secure, confidential, and a safe environment for research participants. 17 For example, this allows the researchers to create ground rules for discussion which detail what style, tone, and content of messages would be appropriate for discussions to ensure the well-being of all participants. 17 AVFGs also allow the researchers to access participants regardless of location, which is likely to be an obstacle with rare diseases such as PSC. When the AVFGs are ongoing, the researchers will check the content twice daily to ensure safety for all parties involved. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 All interviews are expected to last a maximum of one hour. Many healthcare professionals face considerable time constraints in their workplace and so the interview will be constructed to take as little time as possible. Participation is entirely voluntary. Given the potential distance of participants, these will be conducted over the phone or via Telemedicine, depending upon the person's preference. The opportunity to talk face-to-face or via email will be offered to local participants should they prefer to do so. Participants will be asked to give verbal audio recorded consent and consent to their interview being audio-recorded. The questions within the interview will focus on similar themes as the AVFGs, but the narrative interview format will allow for a deeper exploration of people's experiences. Should any participant become distressed during the interview, they will be asked if they would like to discontinue the interview or the recording. At the conclusion of each interview, the researcher will debrief with the participant to check how they are feeling and offer contact details for helplines if needed.
Analysis
The data collected from Stage One will be transcribed, coded and de-identified, and then analysed thematically and narratively using NVivo as the data management system. 18 The first researcher will go through the transcripts from the AVFGs and the different interviews and compare themes and narratives between and within the three different groups (people with PSC, partners and family members of people with PSC, healthcare professionals). Themes and narratives will be double-checked by a second researcher, and any disagreements discussed and resolved.
Findings will then be taken to the PSC Support Study Steering Committee to discuss in terms of what has been found, and whether anything has been missed by the researchers and would be an important inclusion in terms of creating the Personalised Psychological Intervention framework. Following this, the group of gastroenterology, hepatology and mental health professionals will then be invited to attend a face-to-face roundtable meeting to discuss ideas and issues that could ground a 'Personalised Psychological Intervention for PSC' framework of recommendations, in conjunction with those with lived experience. This innovative framework of recommendations could help tailor interventions to not only the individuals diagnosed with PSC, but also their partners and families, to ensure they received the best support for their physical and mental health. Further, although the details would be personalised to each individual depending on their symptoms and severity, the framework of these 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y   10 interventions could then be shared to the wider healthcare professional community so they would be better prepared to support a patient diagnosed with PSC. Again, this framework will then be shared with the PSC Support steering group to ensure that it is pragmatic and practical in terms of what people with PSC need in terms of care and support in their everyday lives. 
ETHICS and DISSEMINATION
Ethical Approval
Informed consent
Informed consent will be obtained for each participant. All participants will be provided with an information sheet indicating the purpose of the study and will have an opportunity to ask questions. Consent for participants partaking in the AVFGs will be recorded online. Formal consent will also be recorded for all those taking part in narrative interviews. Should interviews be carried out over telephone or via Telemedicine, participants will be asked to give verbal consent which will be audio-recorded. Signed and written consent will be sought from those taking part in face-to-face or email interviews. Consent from all members taking part in a roundtable discussion will be audio-recorded.
Data protection and patient confidentiality
Information provided in confidence will be anonymised and not be used or disclosed in a form that might identify the participant without his or her express written consent. Participants will be given the opportunity to choose their own pseudonym and these will be held in password protected databases on an encrypted NHS server at the Tavistock and Portman NHS Foundation Trust. Only the Chief Investigator and researchers will have access to it, and only anonymised data will be shared with anyone else. Only participants' unique pseudonyms will be linked to the raw data collected (e.g. audio recordings). Audio files will be identified by pseudocodes, however it is possible that names of people and/or places may be mentioned during the interviews. All digital data files (including audio files) will be assigned a pseudocode and uploaded onto a secure NHS server as soon as possible after data is collected, and the files deleted from the memory disk or hard drive. Memory disks and hard drives containing data will be held in locked cabinets if it is not possible to upload the files immediately following data collection. Data will be uploaded onto the secure server, only accessible by authorised researchers, and will be transferred to a trusted transcription company using secure data transfer methods. All members of the research team will be reminded of their duty to observe the NHS code of ethics regarding patient confidentiality.
Dissemination
The findings of the study will be submitted for publication in peer-reviewed journals, and will be presented nationally. All intellectual property rights relating to the data arising from the study shall be held by the Tavistock & Portman NHS Foundation Trust. Participants who consent to receive the study findings will be sent an electronic or hard copy interim report and a final lay summary of the findings, depending on their preferred method of communication. They will also be provided with the details of where to access the online publication of the full study report. 
Patient and Public Involvement:
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Limited voices from lived experience suggest that living with PSC can cause considerable psychological distress. This study, therefore, aims to explore how the illness impacts the psychological wellbeing of those living with the illness, and those supporting them. It also aims to create a personalised psychological intervention to support all groups.
Methods and analysis This project will take a layered qualitative approach to understanding the ways in which people experience living with PSC within their day-to-day lives. There will be two stages to this study, which will pilot a unique methodological process using online resources. The first stage will consist of Asynchronous Virtual Focus Groups (AVFGs) with those living with PSC and those who provide support for those diagnosed with PSC, and narrative interviews with both groups and health professionals. Both the AVFGs and the narrative interviews will be analysed using thematic narrative analysis. The second stage will comprise a roundtable discussion where the researchers and health professionals will devise a personalised psychological intervention to help support those living with PSC and their supporters. The study duration is expected to be 18 months.
Ethics and dissemination The proposed study has been approved by the UK Health Research
Authority and London -Queen Square Research Ethics Committee as application 18/LO/1075.
Results from the AVFGs and narrative interviews will be submitted for peer-reviewed publication. The findings of the study will also be presented nationally to PSC and medical communities, and a summary of the findings will be shared with participants. 
ARTICLE SUMMARY
Strengths and limitations:
 This study will employ innovative qualitative research methods, such as the use of asynchronous virtual focus groups (AVFGs), to capture the lived experiences of those with a rare illness spread over a large geographic space who would not be able to participate in a study like this otherwise.  A triangulated perspective will be used to explore the experiences of those living with PSC, caregivers and health professionals, with a view to improving the support provided to all.  A personalised psychological intervention, that can be tailored to fit individuals' personal circumstances, will be created in response to analysing these experiences.  However, involvement in AVFGs is dependent on participants' literacy, computerliteracy and access to technology.  Although online qualitative approaches can target difficult-to-access populations, they cannot replace face-to-face human contact and interaction. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 estimates suggest that the incidence of PSC is 0.68 per 100,000 person-years. 2 It disproportionately affects men, and symptoms include jaundice, fatigue, and itching, among others. 1, 3 However, these symptoms vary: some people are asymptomatic when first diagnosed, whereas others have a significant symptom burden. 4 In addition to this variation in symptoms, the speed and aggressiveness with which the disease can progress may differ between individuals, with little indication from the literature as to why. 1 Furthermore, there is no curative treatment for PSC, with liver transplant offered as an option for those reaching endstage liver disease, with those living with the illness displaying a greater incidence of colorectal and biliary tract cancers in addition to other complications. 5, 6 In the absence of curative treatment, recent research has begun to examine the impact of living with PSC on individuals' psychological wellbeing. 7 Similar to other long-term physical illnesses, individuals living with PSC tend to report a greater number of depressive symptoms, and a greater level of impairments pertaining to quality of life and wellbeing compared to the general population. [7] [8] [9] Voices from lived experience reveal that the uncertainty with which the disease may progress to an eventual need for a liver transplant, and whether and when that transplant may be possible, can lead to considerable distress and anxiety regarding the future. 10, 11 In addition to such distress, individuals with PSC also report feeling socially isolated due to the rarity of the illness. 8, 12 Consequentially, such difficulties emphasise a need for access to emotional support that addresses this population's unmet needs and reinstalls hope in the future. 10 A need for greater access to support is likely also felt by those supporting individuals living with PSC, whether informally or formally. 7 Partners and families supporting those living with PSC may need to adjust and prepare for caring for a serious illness. Due to the rarity of the illness, few healthcare professionals will have experience of how PSC can present and progress, and so treating the presenting individual may result in unexpected challenges for them, especially in finding appropriate and effective pathways of care for their patient. 11 In light of these difficulties, the proposed study will aim to understand and chronicle the impact of PSC on the psychological wellbeing of those diagnosed with it and their caregivers, and on 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
METHODS and ANALYSIS
Procedure
This project will take a layered qualitative approach to understanding the ways in which people experience living with PSC within their day-to-day lives. There will be two stages to this study, which will also pilot a unique methodological process using online resources. The study duration is expected to be 18 months. AVFGs are focus groups held online over a time period that is longer than a usual focus group, usually one question per week over a period of several weeks. Similar to a traditional focus group, they still have set time limits and the ability for participants to engage with each other. They have been previously used successfully with vulnerable and diverse populations. 13 As PSC is so rare, conducting face-to-face research is difficult, so AVFGs are a good way of accessing as wide a group as possible. 14 Separate AVFGs will be conducted with both people living with PSC and family members to allow participants to be as open and honest in their responses as they wish.
AVFGs will be held on a virtual learning environment (VLE) platform and will be limited to 6-9 participants per group. Due to their online nature, more than one AVFG will be held at the same time. Participants will be asked to answer a different question each week for four weeks, relating to their experiences of receiving a diagnosis of PSC, their experiences with healthcare professionals, what helps or hinders their wellbeing, and what advice they would share with someone recently diagnosed with PSC. one question will be posed per week and the participants can post as many responses as they wish each week; both in response to the question posed and what other responders have said. After a week, the previous question will be closed and the next one will be opened; this will be clearly stated. In this way, participants can respond when it suits them, with the responses being as long or as short as they feel comfortable with. The AVFGs will be moderated twice daily by researchers KM and VR to check the content of what is posted by participants. Participants will be asked to follow a series of common 'netiquette' guidelines, for instance asking participants to respect other participants' points of view and refraining from using all caps. Should the moderators see evidence of severe psychological distress, researchers KM and VR will make direct contact with participants and redirect them towards the appropriate support. Every participant will also have online access to clear contact details for the research team and helplines (ie. Samaritans) for the duration of the study. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y   7 Narrative interviews are crucial to unpacking the themes identified from the AVFGs to inform the development of a personalised psychological intervention. Narrative interviews will be conducted with: a) A purposive sample of participants living with PSC and family members who participated in the AVFGs, and b) Healthcare professionals recruited either via PSC support or from asking those living with PSC who took part in AVFGs if they are willing to provide the name and contact details of their healthcare practitioner. As PSC is uncommon, it is expected that not every healthcare practitioner will be experienced in treating it, which can lead to feelings of stress when trying to determine the best pathway of care for their patient.
Sample
Participants must:
 Be aged 18 years or more 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 it is difficult to specify the size of our sample. The study will aim to include a range of 37-62 participants overall. This range acknowledges that recruitment of individuals with PSC may be challenging given the rarity of the illness, but also ensures enough participation for data saturation. For the AVFGs we aim to run 2 -4 focus groups consisting of 6 -9 participants in each. This will include: 1 -2 focus groups of people living with PSC and 1 -2 focus groups of partners and family members of people living with PSC. From these, we plan on purposively sampling up to ten individuals to take part in narrative interviews. Additionally, we aim to interview 5 -10 health professionals.
Setting
Asynchronous Virtual Focus Groups (AVFGs) will be hosted on an existing Virtual Learning Environment (VLE) (ie. Moodle or Blackboard). 15, 16 VLEs are suitable for collecting this type of data as they enable researchers to host focus groups on their own custom-made site which is secure, confidential, and a safe environment for research participants. 17 For example, this allows the researchers to create ground rules for discussion which detail what style, tone, and content of messages would be appropriate for discussions to ensure the well-being of all participants. 17 AVFGs also allow the researchers to access participants regardless of location, 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y   9 which is likely to be an obstacle with rare diseases such as PSC. When the AVFGs are ongoing, the researchers will check the content twice daily to ensure safety for all parties involved.
All interviews are expected to last a maximum of one hour. Many healthcare professionals face considerable time constraints in their workplace and so the interview will be constructed to take as little time as possible. Participation is entirely voluntary. Given the potential distance of participants, these will be conducted over the phone or via Telemedicine, depending upon the person's preference. The opportunity to talk face-to-face or via email will be offered to local participants should they prefer to do so. Participants will be asked to give verbal audio recorded consent and consent to their interview being audio-recorded. The questions within the interview will focus on similar themes as the AVFGs, but the narrative interview format will allow for a deeper exploration of people's experiences. Should any participant become distressed during the interview, they will be asked if they would like to discontinue the interview or the recording. At the conclusion of each interview, the researcher will debrief with the participant to check how they are feeling and offer contact details for helplines if needed.
Analysis
The data collected from Stage One will be transcribed, coded and de-identified, and then analysed thematically and narratively using NVivo as the data management system. 18 The first researcher (VR) will go through the transcripts from the AVFGs and the different interviews and analyse these using thematic narrative analysis. This will involve comparing themes and narratives both chronologically and between the three different groups (people with PSC, partners and family members of people with PSC, healthcare professionals). Themes and narratives will be double-checked by a second researcher (KM), and any disagreements discussed and resolved between the two researchers.
Findings will then be taken to the PSC Support Study Steering Committee to discuss in terms of what has been found, and whether anything has been missed by the researchers and would be an important inclusion in terms of creating the Personalised Psychological Intervention framework. Following this, the group of gastroenterology, hepatology and mental health professionals will then be invited to attend a face-to-face roundtable meeting to discuss ideas and issues that could ground a 'Personalised Psychological Intervention for PSC' framework of recommendations, in conjunction with those with lived experience. This innovative 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 F o r p e e r r e v i e w o n l y 10 framework of recommendations could help tailor interventions to not only the individuals diagnosed with PSC, but also their partners and families, to ensure they received the best support for their physical and mental health. Further, although the details would be personalised to each individual depending on their symptoms and severity, the framework of these interventions could then be shared to the wider healthcare professional community so they would be better prepared to support a patient diagnosed with PSC. Again, this framework will then be shared with the PSC Support steering group to ensure that it is pragmatic and practical in terms of what people with PSC need in terms of care and support in their everyday lives.
Patient and Public Involvement
The study was co-designed with PPI involvement from PSC Support, and will be overseen by a steering committee composed of individuals living with PSC or caring for relatives living with PSC. The study will be advertised by PSC Support and its findings will be evaluated and disseminated by members of PSC Support. 
ETHICS and DISSEMINATION
Ethical Approval
Informed consent
Informed consent will be obtained for each participant. All participants will be provided with an information sheet indicating the purpose of the study and will have an opportunity to ask questions. Consent for participants partaking in the AVFGs will be recorded online. Formal consent will also be recorded for all those taking part in narrative interviews. Should interviews be carried out over telephone or via Telemedicine, participants will be asked to give verbal consent which will be audio-recorded. Signed and written consent will be sought from those taking part in face-to-face or email interviews. Consent from all members taking part in a roundtable discussion will be audio-recorded. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 F o r p e e r r e v i e w o n l y 11 Information provided in confidence will be anonymised and not be used or disclosed in a form that might identify the participant without his or her express written consent. Participants will be given the opportunity to choose their own pseudonym and these will be held in password protected databases on an encrypted NHS server at the Tavistock and Portman NHS Foundation Trust. Only the Chief Investigator and researchers will have access to it, and only anonymised data will be shared with anyone else. Only participants' unique pseudonyms will be linked to the raw data collected (e.g. audio recordings). Audio files will be identified by pseudocodes, however it is possible that names of people and/or places may be mentioned during the interviews. All digital data files (including audio files) will be assigned a pseudocode and uploaded onto a secure NHS server as soon as possible after data is collected, and the files deleted from the memory disk or hard drive. Memory disks and hard drives containing data will be held in locked cabinets if it is not possible to upload the files immediately following data collection. Data will be uploaded onto the secure server, only accessible by authorised researchers, and will be transferred to a trusted transcription company using secure data transfer methods. All members of the research team will be reminded of their duty to observe the NHS code of ethics regarding patient confidentiality.
Data protection and patient confidentiality
Dissemination
The findings of the study will be submitted for publication in peer-reviewed journals, and will be presented nationally. All intellectual property rights relating to the data arising from the study shall be held by the Tavistock & Portman NHS Foundation Trust. Participants who consent to receive the study findings will be sent an electronic or hard copy interim report and a final lay summary of the findings, depending on their preferred method of communication. They will also be provided with the details of where to access the online publication of the full study report. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Purpose or research question -Purpose of the study and specific objectives or questions 4
Methods
Qualitative approach and research paradigm -Qualitative approach (e.g., ethnography, grounded theory, case study, phenomenology, narrative research) and guiding theory if appropriate; identifying the research paradigm (e.g., postpositivist, constructivist/ interpretivist) is also recommended; rationale** 6-7
Researcher characteristics and reflexivity -Researchers' characteristics that may influence the research, including personal attributes, qualifications/experience, relationship with participants, assumptions, and/or presuppositions; potential or actual interaction between researchers' characteristics and the research questions, approach, methods, results, and/or transferability N/A Context -Setting/site and salient contextual factors; rationale** 8-9
Sampling strategy -How and why research participants, documents, or events were selected; criteria for deciding when no further sampling was necessary (e.g., sampling saturation); rationale** 7-8
Ethical issues pertaining to human subjects -Documentation of approval by an appropriate ethics review board and participant consent, or explanation for lack thereof; other confidentiality and data security issues 10-11
Data collection methods -Types of data collected; details of data collection procedures including (as appropriate) start and stop dates of data collection and analysis, iterative process, triangulation of sources/methods, and modification of procedures in response to evolving study findings; rationale** 5-8 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 F o r p e e r r e v i e w o n l y 3 **The rationale should briefly discuss the justification for choosing that theory, approach, method, or technique rather than other options available, the assumptions and limitations implicit in those choices, and how those choices influence study conclusions and transferability. As appropriate, the rationale for several items might be discussed together. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 
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